Differences in research funding for women scientists: a systematic comparison of UK investments in global infectious disease research during 1997–2010

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1136/bmjopen-2013-003362

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879264

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
BMJ Open  Differences in research funding for women scientists: a systematic comparison of UK investments in global infectious disease research during 1997–2010

Michael G Head,1 Joseph R Fitchett,2 Mary K Cooke,1 Fatima B Wurie,1 Rifat Atun3,4

ABSTRACT

Objectives: There has not previously been a systematic comparison of awards for research funding in infectious diseases by sex. We investigated funding awards to UK institutions for all infectious disease research from 1997 to 2010, across disease categories and along the research and development continuum.

Design: Systematic comparison.

Methods: Data were obtained from several sources for awards from the period 1997 to 2010 and each study assigned to—disease categories; type of science (preclinical, phases I–III trials, product development, implementation research); categories of funding organisation. Fold differences and statistical analysis were used to compare total investment, study numbers, mean grant and median grant between men and women.

Results: 6052 studies were included in the final analysis, comprising 4357 grants (72%) awarded to men and 1695 grants (28%) awarded to women, totalling £2.274 billion. Of this, men received £1.786 billion (78.5%) and women £488 million (21.5%). The median value of award was greater for men (£179 389; IQR £59 146–£371 977) than women (£125 556; IQR £78 520–£261 834). Awards were greater for male principal investigators (PIs) across all infectious disease systems, excepting neurological infections and sexually transmitted infections. The proportion of total funding awarded to women ranged from 14.3% in 1998 to 26.8% in 2009 (mean 21.4%), and was lowest for preclinical research at 18.2% (£285.5 million of £1.573 billion) and highest for operational research at 30.9% (£151.4 million of £489.7 million).

Conclusions: There are consistent differences in funding received by men and women PIs; women have fewer funded studies and receive less funding in absolute and in relative terms; the median funding awarded to women is lower across most infectious disease areas, by funder, and type of science. These differences remain broadly unchanged over the 14-year study period.

INTRODUCTION

Women are under-represented in biomedical science, yet few studies have systematically explored the extent and reasons for the observed differences between men and women scientists. Women comprise 50% of the European Union (EU) student population and 45% of doctoral students, but only one-third of career researchers are women—a figure that is lower for senior positions.

In 2001, a Wellcome Trust survey concluded that although women were as successful as men in securing funding for biomedical research, they were less likely to apply for grant funds because of their status in scientific institutions and the level of support they received. An analysis of Wellcome Trust awards in 2000–2008 revealed a significant gender difference in the amount of funding awarded, even after adjusting for the seniority of the principal investigator (PI), concluding “the most likely explanation for the difference in amounts awarded to women and men is that women are...
systematically less ambitious in the amounts of funding requested in their grant applications.\textsuperscript{25} In 2011, around 44% of academics in UK universities were women, yet only 39% of senior lecturers and 19% of professors were women.\textsuperscript{3} Furthermore, a number of studies from the USA have shown that women in science are disadvantaged compared to men.\textsuperscript{5–7}

The low numbers of women in science and the reasons for this anomaly are a matter of concern for scientists and policy-makers. Although the UK Medical Research Council (MRC) has a gender equality scheme, which briefly states that gender equality is reflected in agreements with research organisations receiving MRC funding, it is not clear how the scheme is implemented.\textsuperscript{8}

While several initiatives have aimed to increase the numbers of women involved in science, there are no affirmative actions or binding policies in the UK or Europe to definitively ensure that women are better represented in science. Indeed, some initiatives aimed at increasing women in science have been criticised. For example, in 2012, the European Commission campaign targeting 13-year-old to 18-year-old secondary school students\textsuperscript{9} was rebuked and described as an insult to women in science,\textsuperscript{10 11} with the offending video clip removed from the EU campaign website. The effects of campaigns aimed at raising the profile of women in science\textsuperscript{12 13} have not been assessed.

We have previously undertaken a systematic analysis of research funding awarded to UK institutions for all infectious disease research for the 14-year period from 1997 to 2010.\textsuperscript{14} Here, we use the dataset gathered for this earlier study to examine trends over time, the distribution of funding awarded to men and women PIs across specific infections, funder categories and along the research and development (R&D) continuum, extending from preclinical to clinical and operational research.

**METHODS**

We obtained data from several sources for infectious disease research studies where funding was awarded between 1997 and 2010. The methods for the original study are elaborated in detail elsewhere\textsuperscript{14} and summarised here. We identified 325,922 studies for screening that covered all areas of disease from several funders, and filtered these to identify funding for infectious diseases where the lead institution was in the UK in the period and the year of award 1997–2010. We obtained data from publicly available sources and directly from the funders. We did not include private sector funding in the analysis, as pharmaceutical sector data were not publicly available. Figure 1 shows the sources of data and the numbers of studies included and excluded at each stage of screening to reach the final set of studies for detailed analysis.

Data collection and cleaning took place alongside routine duties between 2006 and 2011, primarily by MGH and assisted by JRF, MKC and FBW. Funding records could feasibly be obtained going back to 1997, hence the decision to cover awards during 1997–2010. We assigned each study to primary disease categories, and within each category we documented topic-specific subsections, including specific pathogen or disease. We allocated studies to one of four categories along the R&D continuum: preclinical; phases I, II or III; product development; and operational research, and to 1 of the 26 categories for funding organisations.

Where the PI was named, we assigned them to men or women categories. The studies where only an initial was available for the forename were assigned as ‘unclear’ if we were unable to establish the PIs gender from a review of the literature, institutional websites or publicly available publications and documents.

Reference to sexually transmitted infections excludes HIV. Neglected tropical diseases were categorised according to the classification used by the WHO (http://www.who.int/neglected_diseases/diseases/en). Antimicrobial resistance includes antibacterial, antiviral, antifungal and antiparasitic studies.

We converted grants awarded in a currency other than pounds sterling to UK pounds using the mean exchange rate in the year of the award. We adjusted grant funding amounts for inflation and reported in 2010 UK pounds.

As well as excluding studies not immediately relevant to infection, we excluded unfunded studies, veterinary infectious disease research studies (unless there was a zoonotic component), those exploring the use of viral vectors to investigate non-communicable diseases, grants for symposia or meetings or studies with UK contributions (eg, as a collaborator), but the funding was awarded to a non-UK institution.

We used Microsoft Excel versions 2000 and 2007 to categorise studies. Where needed, data were exported into Microsoft Access (versions 2000 and 2007) and specific keyword queries used to select precise sections of the data for analysis. We used Stata (V.11.0) for statistical analysis and to generate figures.

We used fold differences to compare total investment, number of studies, mean grant and median grant between men and women according to disease system, specific infection and funding organisation.

We used the non-parametric Mann-Whitney rank-sum test to assess the distribution of funding by gender. The non-parametric K-sample test on equality of medians was applied to compare the median funding by gender, and reported as a $\chi^2$ statistic without Yates’ correction for continuity. The non-parametric Wilcoxon signed-rank test was applied when comparing matched data, such as time trends by gender. The significance for all tests was defined at the 5% level (two-sided $p<0.05$).

We present differences between gender and do not attempt to investigate or imply bias or inequalities as we could not access data on unsuccessful grant applications.
RESULTS
We identified 6165 studies from the 325,922 studies screened that were suitable for inclusion in our analysis. Of these, we were unable to ascertain the gender of the PI for 30 studies (0.5%). We excluded 83 studies (1.3%) that did not specify the PI’s name or gender—these were funded by the Bill & Melinda Gates Foundation (Gates Foundation; 38 studies; 0.6%) and the UK Department for International Development (DFID; 22 studies; 0.4%), accounting for £321.2 million (12.3% of the total). We included 6052 studies in the final analysis, comprising 4357 grants (72%) awarded to men and 1695 grants (28%) awarded to women, totalling £2.274 billion, of which £1.786 billion (78.5%) were awarded to men and £488 million (21.5%) to women.

The median value of grant funding was greater for men (£179 389; IQR £59 146–£371 977) than for women (£125 556; IQR £30 982–£261 834). Similarly, the mean

---

Figure 1  Methodology flow chart for filtering studies first by infectious disease and then by gender. BBSRC, Biotechnology and Biological Sciences Research Council; ESRC, Economic and Social Research Council; PI, principal investigator; R&D, research and development.
value of the grant funding was greater for men (£409,910; SD £840,087) than for women (£288,011; SD £704,474). Figure 2 shows the distribution of the total investments and median funding awarded to PIs by gender over time.

**Infectious disease system**

Table 1A (see web appendix 1) shows the total investment, total numbers of studies, mean grant funding, median grant funding and fold differences in funding according to nine disease systems and by gender of PI. We identified no infectious disease system where women led the majority of research efforts or were awarded the majority of funding. Median funding awards were greater for male PIs across all infectious disease systems, with the exception of neurological infections and sexually transmitted infections.

The greatest levels of funding awarded to men and to women were for research into respiratory infections and HIV. Men received a total of £312.1 million for research into respiratory infections compared with £84.4 million for women—a 3.70-fold difference—and a total of £290.8 million for HIV research compared with £79.7 million for women—a 3.65-fold difference.

The largest difference between total funding for men and for women was with gastrointestinal infections (5.65-fold difference) where women received only 15% of the total investment (£37 million) and spearheaded 18.9% (149) of the studies and neurological infections (4.22-fold difference). The smallest difference between

---

**Figure 2** (A) Total investment over time awarded to male and female principal investigators. (B) Median investment over time awarded to male and female principal investigators.

---

total funding for men and for women was in research into sexually transmitted infections (1.90-fold difference), where women received 35% (£45.4 million) of the total funding and led 49% (182) of the studies.

The mean funding for grants was significantly greater for men (£409,910; SD £840,087) than for women (£288,011; SD £704,474). The differences in median funding were statistically significant (p<0.01) for gastrointestinal infections (men £328,021; SD £458,720) and for haematological infections (men £417,889; SD £914,626) (women £248,615; SD £433,176), for hepatitis C (men £124,797; IQR £42,475–£289,293) (women £67,265; IQR £29,880–£233,467), for influenza (men £348,730; IQR £213,601–£668,561) (women £200,787; IQR £124,210–£398,191), for herpes simplex virus (men £119,295; IQR £40,009–£446,395) (women £309,610; IQR £147,885–£439,305) and for HIV (men £163,462; IQR £39,153–£511,800) (women £114,272; IQR £29,880–£305,339).

The median funding for grants showed a similar pattern, with a significantly greater grant funding for men (£179,389; IQR £59,146–£371,977) than women (£125,556; IQR £30,983–£261,835). Differences in median funding were statistically significant (p<0.05) for gastrointestinal infections (men £208,369; IQR £78,852–£306,126; SD £819,910) and for HIV (men £118,638; IQR £43,637–£155,066; IQR £43,637–£155,066; SD £819,910) and for herpes simplex virus (men £119,295; IQR £40,009–£446,395) (women £309,610; IQR £147,885–£439,305) and for HIV (men £163,462; IQR £39,153–£511,800) (women £114,272; IQR £29,880–£305,339).

**Specific infections**

Table 1B (see web appendix 1) shows total investment, total numbers of studies, mean grant funding, median grant funding and fold differences in funding according to specific infection by gender.

Men received significantly higher levels of total research funding, spearheaded greater numbers of studies and were awarded greater median and mean funding for grants for malaria (p<0.01), HIV (p<0.01) and influenza (p<0.01). However, for hepatitis C (p=0.01), HIV (p=0.04) and for respiratory syncytial virus (p=0.01), differences were only statistically significant for women. Differences between funding awarded to men and to women were by the UK Government funding streams such as the National Institute for Health Research, with a 1.66-fold difference. Mean grant funding from public funding organisations was significantly greater for men at £595,361 (SD £1,080,718) than for women at £544,427 (SD £884,442) and for UK Government grants with men at £208,828 (SD £492,519) and women at £182,907 (SD £619,889).

Funding organisation

Table 2 (see web appendix 2) shows in detail the total investment, total numbers of studies, mean grant funding, median grant funding and fold differences in funding according to funding organisation and by gender.

Public funding organisations invested a total of £1,025 billion in research led by men (78.6%) and £279.8 in research led by women (21.4%). The greatest levels of funding awarded to men and to women were by the Wellcome Trust and the UK MRC. Major differences between funding awarded to men and to women PIs were by the Biotechnology and Biological Sciences Research Council (BBSRC), with a 6.12-fold difference. Smallest differences between funding awarded to men and to women were by the UK Government funding streams such as the National Institute for Health Research, with a 1.66-fold difference.

Mean grant funding from public funding organisations was significantly greater for men at £395,361 (SD £1,080,718) than for women at £348,414 (SD £814,979). Differences were also statistically significant (p<0.01) for UK MRC grants with men at £751,413 (SD £1,020,748) and women at £544,427 (SD £884,442) and for UK Government grants with men at £208,828 (SD £492,519) and women at £182,907 (SD £619,889).

Median grant funding from public funding organisations had a similar pattern with significantly greater grant funding for men at £272,452 (IQR £138,322–£572,529) and women at £213,718 (IQR £92,880–£402,917). Differences were also statistically significant (p<0.05) for UK MRC grants with men at £404,615 (IQR £210,068–£811,860) and women at £286,629 (IQR £178,182 to £468,998), and for UK Government grants with men at £129,660 (IQR £23,761–£207,320) and women at £59,976 (IQR £12,564–£155,066).

Philanthropic funding organisations invested a total of £691.7 million in research led by men (78.8%) and £185.9 million in research led by women (21.2%).
Mean grant funding from philanthropic funding organisations was significantly greater for men at £338,396 (SD £695,025) than for women at £242,014 (SD £711,420). Differences were also statistically significant (p>0.01) for Wellcome Trust grants with men receiving £393,652 (SD £723,549) and women £230,168 (SD £362,836) and for other charitable funding organisations with men receiving £211,190 (SD £454,108) and women £271,842 (SD £1,208,852).

Median grants from philanthropic funding organisations showed a similar pattern with significantly greater grant funding for men at £153,653 (IQR £58,589–£302,774) and women at £114,173 (IQR £42,658–£222,842). Differences were also statistically significant (p>0.05) for Wellcome Trust grants with men receiving £211,190 (IQR £74,759–£362,424) and women £137,241 (IQR £54,019–£250,723), and for other charitable funding organisations with men receiving £91,991 (IQR £36,429–£172,497) and women £76,058 (IQR £17,279–£150,727).

Figure 4 shows the association between funding organisation and total investment and median funding by gender. The MRC awarded the highest median amount in grants to women (£286,679; IQR £178,182–£468,998), but the median funding amount in grants for men were 1.41-fold higher than that awarded to women (£404,615; IQR £210,068–£811,860). The European Commission awarded the highest mean grants to women at £923,364 (SD £1,316,016); however, mean funding amount in grants for men was 1.44-fold higher at £1,325,149 (SD £2,409,860) than that for women.

**Time trend**

Table 3 (see web appendix 3) shows in detail the trends in funding over time from 1997 to 2010 by gender of...
PIs, with amounts and relative proportions each year of funding. Mean annual funding received was greater by men at £127.6 million (SD £48.7 million) than women at £34.9 million (SD £13.4 million). Proportions of annual funding received by men ranged from 73.2% to 85.7%, with a mean of 78.6%.

Proportions of annual funding received by women ranged from 14.3% to 26.8% with a mean of 21.4%. The largest annual funding received by men was £245.7 million in 2000, and the smallest at £64.2 million in 1997. The largest annual funding received by women was £59.6 million in 2002, with the smallest at £13.1 million in 1998.

Over the 14-year study period, the proportion of investment awarded to women each year remains relatively unchanged with a mean of 21.4% of total (range 14.3–26.8%; £13.1 million to £59.6 million). Figure 5 shows the funding trends over time and fold differences in total investments by gender. The absolute difference in the funding amounts in the grants awarded to men and women ranges between £47.9 million and £190.1 million, with a mean difference of £92.7 million (SD £38.3 million). The fold difference in grant funding for men and women ranged from 2.74 to 5.97, with a mean fold difference of 3.66.

**DISCUSSION**

We present the first detailed and systematic comparison by sex of investments in infectious disease research in the UK for the 14-year period 1997–2010. We identified 6165 studies funded by public and philanthropic funding organisations, with a total research investment of £2.6 billion.
We quantified the differences in research funding awarded by gender to show these to be substantial. The analysis shows clear and consistent differences between men and women PIs, with lower funding in terms of the total investment, the number of funded studies, the median funding awarded and the mean funding awarded across most of the infectious disease areas funded. Women received less funding in absolute amounts and in relative terms, by funder and the type of science funded along the R&D pipeline. These differences in funding between men and women persist over time.

We show large differences in median funding amounts for men and women researchers in investments by the European Commission and the MRC. Such differences were much less apparent when comparing funding from the Department of Health and BBSRC, although the BBSRC awarded 86% of funding to men. The BBSRC almost entirely funds preclinical research, and this matches the increased proportions of preclinical studies being led by male PIs.

Our findings in infectious disease research, the most detailed until now, provide new evidence on differences between men and women researchers to reinforce the concerns raised in earlier studies. Differences that are more marked at senior levels of academia need to be investigated to explain and account for the observed differences.
The reasons why the median awards across most infectious disease conditions should be significantly less for women PIs cannot be deduced from the available data. Thus, it is not possible to recommend interventions to address this phenomenon, given that it is unclear if there is any bias or precisely what mechanisms are at play. The next step may be to investigate success rates by gender to assess how many women are applying and what proportion of the initial request for funding is actually allocated.

There have been suggestions that women are systematically less ambitious in the amounts of funding requested in their grant applications when compared with men who are equivalently ranked academically, and that relatively simple mentoring programmes could at least partially overcome this anomaly. However, there is no evidence supporting these assertions. Others have suggested that systems which ensure PI anonymity during review of grant funding submissions may help reduce the presence of any subtle gender biases, though in practice this approach would be challenging as the experience of PI is a key factor when considering the suitability of request for research support. However, evidence on effective interventions to address barriers for women scientists is lacking. Women of childbearing age are being disadvantaged in some areas of employment, even though in relation to scientific endeavour, productivity as measured by published outputs is not significantly different between women with and without children.

Study limitations

Our analysis has several limitations. We rely on the accuracy of the original data from the funding organisations and, as described elsewhere, we have excluded data from the private sector as the publicly available data are incomplete. In the period analysed, we were not able to find data on the number of men and women PIs requesting financial support for research agencies from the funding sources studies. Hence, we were unable to assess the success and failure rates by gender. We also did not have complete data on the amount of funding initially requested, the gender of coapplicants for each study, the total pool of researchers in each disease area and within each type of science, or the proportion of awards made to clinical and non-clinical researchers, all of which would be useful pieces of information in developing a clearer picture of the reasons for the presented differences. The proportion of doctors registered in the UK favours men (56.8% as of January 2013) over women, but the proportion of those carrying out research appears to be unknown. Understanding the distribution of researchers is critical to an understanding of the research landscape.

We lacked data on the academic ranking of PIs and were hence unable to adjust for levels of seniority across both genders. We were unable to get data on gender from the Gates Foundation and DFID and hence were unable to clarify the gender of a small proportion of investigators, though we believe this limitation is not likely to change the conclusions of the study. Our analysis focuses on infectious disease research, and analysis of other areas of scientific research would be needed if these differences persisted for all research areas.

CONCLUSIONS

Notwithstanding the limitations, our systematic analysis shows an unequal distribution of investments in infectious disease research for men and women. There are fewer women receiving funding as PIs in infectious disease research, with fewer studies funded with lower funding amounts when successful.

Although earlier studies have discussed possible solutions, including mentoring programmes and advertising campaigns, none have systematically explored the reasons why such differences persist. Hence, without an understanding of the reasons for the observed differences, the proposed solutions are not very meaningful. There is no evidence that women and men researchers are not equally capable; hence, other factors are likely to be at play to explain the observed differences which have persisted over the 14-year study period. From our data, the limitations mean that we cannot explain what these mechanisms might be. Research is needed to elucidate an understanding of the factors that can explain the observed differences. A subanalysis of our dataset where information on academic rank at the time of award is obtained would allow for more meaningful conclusions. We strongly urge policy-makers, funders and scientists to urgently investigate the factors leading to the observed differences and develop policies developed to address them, in order to ensure that women are appropriately supported in scientific endeavour.

Author affiliations

1Research Department of Infection and Population Health, University College London, UCL Royal Free Campus, London, UK
2London School of Hygiene & Tropical Medicine, London, UK
3Imperial College London, South Kensington Campus, London, UK
4Harvard School of Public Health, Harvard University, Boston, Massachusetts, USA

Acknowledgements The authors would like to thank Jennifer Harris and Raidah Haider for their input and assistance, and acknowledge the assistance of the research and development funding agencies for provision of data.

Contributors MGH designed the study with input from RA and JF and collated the dataset. JRF, FW and MKC checked and refined the dataset. JRF undertook data analysis and created the graphs and figures with input from MGH and RA. MGH, JRF and RA interpreted the data and wrote the first draft. MGH, JRF and RA refined the analysis and article with input from MKC and FBW. All authors reviewed and approved the final version.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests RA has received research funding from the UK Medical Research Council, the UK National Institute for Health Research, UK CRC, UK EPSRC, the UK Department for International Development and the UK Department of Health. RA is a member of the UL Medical Research Council Global Health Group. MGH works for the Infectious Disease Research Network, which has supported this work and is funded by the UK Department of Health.
JRF has received funds from the Wellcome Trust and is a steering group member for the Infectious Disease Research Network. MKC has received funding from the Medical Research Council and the Bill and Melinda Gates Foundation. FBW has received funds from the UCLH Charitable Foundation.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** All gender data are available with this submission. Further data relating to the Research Investments project can be found at [http://www.researchinvestments.org](http://www.researchinvestments.org) or by contacting MGH.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)

**REFERENCES**


